Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Cash from Financing Activities (2022 - 2024)

CervoMed's Cash from Financing Activities history spans 8 years, with the latest figure at -$13340.0 for Q3 2024.

  • For Q3 2024, Cash from Financing Activities fell 100.12% year-over-year to -$13340.0; the TTM value through Sep 2025 reached -$106715.0, down 100.96%, while the annual FY2024 figure was $46.4 million, 316.16% up from the prior year.
  • Cash from Financing Activities for Q3 2024 was -$13340.0 at CervoMed, up from -$93375.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $11.2 million in Q3 2023 and bottomed at -$93375.0 in Q4 2023.
  • The 3-year median for Cash from Financing Activities is -$5000.0 (2022), against an average of $2.2 million.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 224949.78% in 2023 before it crashed 100.12% in 2024.
  • A 3-year view of Cash from Financing Activities shows it stood at -$5000.0 in 2022, then tumbled by 1767.5% to -$93375.0 in 2023, then skyrocketed by 85.71% to -$13340.0 in 2024.
  • Per Business Quant, the three most recent readings for CRVO's Cash from Financing Activities are -$13340.0 (Q3 2024), -$93375.0 (Q4 2023), and $11.2 million (Q3 2023).